QNTM vs RAPP

Quantum Biopharma Ltd. vs Rapport Therapeutics, Inc. — Valuation Comparison 2026

QNTM

Biotechnology
Quantum Biopharma Ltd.
Quality
1.8
out of 10
Value Trap
Price
$7.02
Last close
Models
9/13
Active
VS

RAPP

Biotechnology
Rapport Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
12
SAFE
Price
$39.49
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType QNTM Fair ValueQNTM Upside RAPP Fair ValueRAPP Upside
Bayesian DCF Intrinsic $1.86 -73.5% $11.30 -71.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.64 -68.9% $3.93 -90.0%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $4.33 -47.2%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for QNTM vs RAPP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QNTM vs RAPP — Which Stock Is More Undervalued?

RAPP scores higher with a 4.2/10 quality rating vs QNTM's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Quantum Biopharma Ltd. (QNTM) and Rapport Therapeutics, Inc. (RAPP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QNTM currently trades at $7.02 with a QOC of 1.8/10, while RAPP trades at $39.49 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).